Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Webcast ImageWebcast
AcelRx Pharmaceuticals, Inc. at Canaccord Genuity Growth Conference (Live)
08/13/14 at 2:30 p.m. ET
AcelRx Pharmaceuticals, Inc. at Canaccord Genuity Growth Conference
Wednesday, August 13, 2014 2:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. AcelRx has announced positive results from each of the three Phase 3 clinical trials for Zalviso and has submitted an NDA to the FDA seeking its approval. AcelRx also announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.
ACRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.22
Change (%) Stock is Down 0.41 (3.86%)
Volume1,777,059
Data as of 07/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

    More >>
07/24/14AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso
REDWOOD CITY, Calif., July 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today confirmed the PDUFA date for Zalviso remains July 27, 2014.  The company recently learned that a rumor circulated online stating the Food and Drug Administration (FDA) had approved Zalviso.  As of July 24, 2014 there has been no notific... 
Printer Friendly Version
07/07/14AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment.  ZALVISOTM is a drug-device combination product ... 
Printer Friendly Version
06/19/14AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference
REDWOOD CITY, Calif., June 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 25th.  Presentation details are as follows: JMP Securities Healthcare Conference Date: Wednesday, June 25th Location: The Westin New York Grand Central, New Yo... 
Printer Friendly Version

Upcoming Events

    More >>
DateTitle
08/13/14 2:30 p.m. ET
AcelRx Pharmaceuticals, Inc. at Canaccord Genuity Growth Conference
LocationInterContinental Hotel
Boston, MA US
08/19/14
AcelRx Pharmaceuticals, Inc. at Guggenheim Securities, LLC One on One Day
LocationIrvine, CA US

Receive E-mail Alerts 

Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AcelRX

CONTACT